Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...

Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...
Yonhap News Agency

[PRNewswire] AAVnerGene Announces AAVone®2.1

ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
The Manila Times

AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest

AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
GEN

Asimov Launches Stable AAV Producer Cell Lines for Viral Vector Manufacturing

Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...
Business Wire

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, AstraZeneca Rare Disease (“Alexion”), for ...

AAVnerGene Inc.: AAVnerGene Announces AAVone2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest

AAVnerGene Inc. today announced the launch of AAVone2.1, the next-generation evolution of its proprietary AAVone single-plasmid AAV production ...